Event Recap: GENDRO at the Twelfth Eurosurveillance Scientific Seminar
GENDRO had the honor of participating in the Twelfth Eurosurveillance Scientific Seminar, whereDr. Shirin Heidari, Founder and Executive Director of GENDRO and lead author of the SAGER Guidelines, delivered a compelling keynote presentation.
Dr. Heidari shared the transformative journey behind the development and implementation of the SAGER Guidelines, highlighting their role in revolutionizing research practices to promote greater gender equity in scientific publishing. Attendees gained practical insights on how to integrate these guidelines into their work, fostering a more inclusive and equitable research environment.
This session underscored the importance of advancing diversity and inclusion within the scientific community and publishing, inspiring participants to take actionable steps toward closing gender gaps in research.
Thank you to all who joined this impactful discussion and contributed to driving meaningful change!
The session, titled “A Pathway to Change,” explored the critical role of the SAGER Guidelines in addressing gender bias in research and driving systemic change toward a more gender-responsive research ecosystem. Dr. Heidari shared the story behind the development of these essential guidelines, offering valuable insights into how they aim to close the gender data gap and contribute to achieving #HealthForAll.
The event brought together professionals and advocates passionate about advancing gender equity in research, sparking engaging conversations on actionable pathways to create an inclusive and equitable global health landscape.
A big thank you to all participants for joining this inspiring session and contributing to the dialogue on building a fairer, more inclusive research ecosystem.
We were thrilled to host Professor Sara (Meg) Davis from the Digital Health and Rights Project (DHRP) at the University of Warwick and James Kiilu from the University of Nairobi, who presented a preview of their forthcoming report, “Towards People-Centered Digital Health Strategies: Gender, Equity, Rights, and Inclusion.”
This event offered a fantastic opportunity to delve into critical discussions around digital health strategies and their implications for gender and rights. Attendees explored the importance of inclusive approaches that promote equity and inclusion in digital health.
As part of GENDRO’s GEH Network, this session brought together actors from academia, civil society, UN agencies, and other entities to share the latest developments and discuss opportunities to promote the integration of sex and gender dimensions in research, innovation, data analysis, health policies, and programs.
Thank you to everyone who joined us for this impactful discussion. Together, we continue to foster dialogue and collaboration to advance equity and rights in digital health!
Gendro participated at the World Cancer Congress 2024 as part of a pivotal plenary session organized by The Lancet commission on Women, Power and Cancer.
UICC has closed a successful World Cancer Congress 2024 in Geneva, where more than 2,000 delegates from over 120 countries discussed global strategies and new approaches to addressing essential challenges facing the cancer community.
The World Cancer Congress 2024 in Geneva, Switzerland, took place 17-19 September. Organised by UICC, the event gathered over 2,000 delegates from more than 120 countries, including UICC members, researchers, healthcare professionals, private sector representatives and advocates, to focus on key themes such as cancer prevention, care, and global policy. Read more ….
In the realm of global health policy and research, persistent and historical gender biases continue to permeate a largely patriarchal ecosystem. These biases result in the oversight of crucial gender dimensions and disadvantage women’s health, hindering adequate investment and innovation tailored to address women’s unique and diverse health needs.
Despite growing awareness of these biases and increased efforts by civil society, academia, and the philanthropic sector (such as the White House Initiative on Women’s Health Research, and the Women’s Health Innovation Opportunity Map by NIH and the Bill & Melinda Gates Foundation) to spur gender responsive and inclusive research and innovation to advance women’s health, progress remains slow and fragmented.
In two sessions, we will delve into the landscape of women’s health research and development (R&D), examining the existing barriers and disparities through a gender lens. Our conversation aims to connect the dots between persistent gender biases in research and the transformative potential of a feminist global health policy (FGHP). By shining a spotlight on the barriers and obstacles in advancing women’s health R&D, we seek to explore whether a FGHP holds the potential to accelerate the discovery and enhance the accessibility of new innovations, crucial to interrupting the prevailing health inequities, particularly those that disproportionately affect women.
Part 1 ‘Gender biases in Research & Development’ aims to explore whether a feminist global health policy (FGHP) is the transformative force needed to disrupt and reconstruct a new global health ecosystem to propel gender equality, address health inequities, and accelerate efforts towards social justice.
Our distinguished panel will shed light on lessons learned from the application of feminist foreign policies, exploring promises and pitfalls of these efforts. The discussion will also include valuable recommendations to spur innovation and advance women’s health in all its diversities.
The objectives of this session are to
Examine gender-related barriers and gender disparities in women’s health research and development, identifying challenges hindering innovation.
Explore the potential impact of a Feminist Global Health Policy in accelerating the discovery and accessibility of innovative solutions to address health inequities for women.
Part 2 ‘Drug drought in Women’s Health’ aims to discuss gaps and strengths of the women’s health R&D landscape in the last 20 year. Together with our distinguished panel of diverse stakeholders, we will discuss where the need for innovation is, and how the future of women’s health R&D looks like. In continuation with part 1, the discussion will also include valuable recommendations to spur innovation and advance women’s health in all its diversities.
The objectives of this session :
Examine gender-related barriers and gender disparities in women’s health research and development, identifying challenges hindering innovation.
Explore the potential impact of a Feminist Global Health Policy in accelerating the discovery and accessibility of innovative solutions to address health inequities for women.
